NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Zhengye Biotechnology Holding Limited (ZYBT) Stock Analysis

Zhengye Biotechnology Holding Limited (ZYBT) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

ZYBT

$1.61

−$0.02 (−1.23%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ZYBT with… →

ZYBT Key Statistics

As of Sep 4, 2026
Trading
Open
$1.66
Previous Close
$1.63
Day's Range
1.60–1.71
52-Week Range
0.62–11.45
Volume
33.50K
Valuation
Market Cap
$76.30M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.66
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.22
Financials (FY)
Revenue (FY)
$116.36M−37.56%
Net Income (FY)
−$69.78M−716.96%
Profit marginThe share of revenue left as profit after all costs and taxes.
−59.97%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
47.39M
1-Year Return
−79.54%
Dividend and dates
Avg Volume
5.25M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ZYBT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+40.00%
2025−76.34%

As of September 4, 2026.

ZYBT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$116.36M−$69.78M−60.0%
2024$186.36M$11.31M6.1%
2023$211.65M$31.46M14.9%
2022$260.27M$46.74M18.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$116.36M$23.87M−$68.25M−$69.78M−60.0%
2024$186.36M$91.30M$17.17M$11.31M6.1%
2023$211.65M$117.51M$47.64M$31.46M14.9%
2022$260.27M$147.88M$66.09M$46.74M18.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ZYBT Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricZYBTDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio0.662.300.3x the median
Profit margin−59.97%−3.14%56.8 pts below

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Zhengye Biotechnology Holding Limited (ZYBT) is capitalised at $76.30M on the latest close. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. The company reports 269 employees.

ZYBT last closed at $1.61 on September 4, 2026. That is −$0.02 (−1.23%) against the previous close. The 52-week range on file runs from $0.62 to $11.45. The latest close sits 161.36% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $116.36M. Against the prior fiscal year total of $186.36M, that is a change of −37.56%. The same year closed with a net loss of $69.78M. The reported profit margin is −59.97%. That is 56.8 percentage points below the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are −0.22.

Across the 4 fiscal years on file, revenue moves from $260.27M in 2022 to $116.36M in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 0.66. On price-to-sales that is 0.3 times the Drug Manufacturers - Specialty & Generic median of 2.3. 103 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

Annualized volatility over the trailing 1 year is 1,063.66%. Over the trailing twelve months the price has returned −79.54%. The stored price history starts on January 7, 2025, and the total return since then is −66.87%.

Growth & Income

The record shows no dividend for ZYBT.

The record holds one complete calendar year, 2025, which returned −76.34%. So far in 2026 the price is +40.00%.

Peer Comparison

Zhengye Biotechnology Holding Limited (ZYBT) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Zhengye Biotechnology Holding Limited ZYBT $76.30M —
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Zhengye Biotechnology Holding Limited has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Zhengye Biotechnology Holding Limited

Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine. It also develops vaccines for household animals, including rabies vaccine and Strain Flury LEP for dogs. In addition, the company exports its products to Vietnam, Pakistan, and Egypt. It serves direct-end customers, including livestock farmers and local governments; and domestic distributors and exporting distributors. The company was incorporated in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited.

Visit website →